FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034289964> ?p ?o ?g. }

• W2034289964 endingPage "662" @default.
• W2034289964 startingPage "649" @default.
• W2034289964 abstract "Purpose: The purpose of the Phase I component of this study was to find the maximally tolerated dose (MTD) of cisplatin administered within a regimen of fever-range whole body thermal therapy (FR-WB-TT), cisplatin, gemcitabine, and low-dose interferon-alpha (IFN-α). The Phase II component aimed to assess which cancer diagnoses responded to the regimen, the response rate, and response duration.Materials and methods: The protocol design derived from a schedule-optimized preclinical regimen. Drugs were administered together, and also with thermal therapy in a schedule that optimized the therapeutic index. Eligible patients were those with therapy-resistant, metastatic or advanced solid malignancies. Beginning at 40 mg/m2, the cisplatin dose was escalated by 10 mg/m2 to the maximally tolerated dose (MTD) in successive cohorts of 3 patients. A treatment cycle consisted of cisplatin on day one, followed by thermal therapy and simultaneous gemcitabine 36 hours later; then a second dose of gemcitabine one week later; and daily IFN- α.Results: Thirty-seven patients were treated on protocol. The MTD of cisplatin in the thermochemotherapy regimen was established to be 60 mg/m2. The dose limiting toxicities (DLT) were peripheral neuropathy and ototoxicity. Complete and partial responses combined were 43%. The therapy improved the quality of life of responding patients.Conclusion: The protocol was well tolerated and was associated with antitumor activity in patients with a variety of advanced metastatic solid tumors. Tumor response occurred with the thermochemotherapy treatment despite treating malignancies that had progressed on the same chemotherapy drugs administered as standard treatment. Notably, good responses were observed in patients with high-grade neuroendocrine and pancreas cancers. This regimen will be tested in a phase II study." @default.
• W2034289964 created "2016-06-24" @default.
• W2034289964 creator A5015428414 @default.
• W2034289964 creator A5017696294 @default.
• W2034289964 creator A5019126926 @default.
• W2034289964 creator A5026905234 @default.
• W2034289964 creator A5029395182 @default.
• W2034289964 creator A5035120459 @default.
• W2034289964 creator A5038730582 @default.
• W2034289964 creator A5049008391 @default.
• W2034289964 creator A5091240925 @default.
• W2034289964 date "2008-01-01" @default.
• W2034289964 modified "2023-10-16" @default.
• W2034289964 title "Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-<b>α</b>: A description of a phase I-II protocol" @default.
• W2034289964 cites W1904205969 @default.
• W2034289964 cites W1968626722 @default.
• W2034289964 cites W1975519852 @default.
• W2034289964 cites W1975748182 @default.
• W2034289964 cites W1982322400 @default.
• W2034289964 cites W1985239297 @default.
• W2034289964 cites W1998206439 @default.
• W2034289964 cites W2001285546 @default.
• W2034289964 cites W2004869577 @default.
• W2034289964 cites W2008355125 @default.
• W2034289964 cites W2013783311 @default.
• W2034289964 cites W2017449430 @default.
• W2034289964 cites W2021177433 @default.
• W2034289964 cites W2023027189 @default.
• W2034289964 cites W2040675026 @default.
• W2034289964 cites W2042378712 @default.
• W2034289964 cites W2044410781 @default.
• W2034289964 cites W2075117403 @default.
• W2034289964 cites W2086342402 @default.
• W2034289964 cites W2089062211 @default.
• W2034289964 cites W2095881540 @default.
• W2034289964 cites W2108540588 @default.
• W2034289964 cites W2109713544 @default.
• W2034289964 cites W2113566724 @default.
• W2034289964 cites W2125385057 @default.
• W2034289964 cites W2127222886 @default.
• W2034289964 cites W2128846699 @default.
• W2034289964 cites W2129336404 @default.
• W2034289964 cites W2140408327 @default.
• W2034289964 cites W2158740848 @default.
• W2034289964 cites W2170783473 @default.
• W2034289964 cites W4244061122 @default.
• W2034289964 cites W4293241248 @default.
• W2034289964 cites W4312850899 @default.
• W2034289964 cites W4376453924 @default.
• W2034289964 doi "https://doi.org/10.1080/02656730802104740" @default.
• W2034289964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18608594" @default.
• W2034289964 hasPublicationYear "2008" @default.
• W2034289964 type Work @default.
• W2034289964 sameAs 2034289964 @default.
• W2034289964 citedByCount "36" @default.
• W2034289964 countsByYear W20342899642014 @default.
• W2034289964 countsByYear W20342899642015 @default.
• W2034289964 countsByYear W20342899642016 @default.
• W2034289964 countsByYear W20342899642017 @default.
• W2034289964 countsByYear W20342899642018 @default.
• W2034289964 countsByYear W20342899642019 @default.
• W2034289964 countsByYear W20342899642020 @default.
• W2034289964 countsByYear W20342899642021 @default.
• W2034289964 countsByYear W20342899642022 @default.
• W2034289964 crossrefType "journal-article" @default.
• W2034289964 hasAuthorship W2034289964A5015428414 @default.
• W2034289964 hasAuthorship W2034289964A5017696294 @default.
• W2034289964 hasAuthorship W2034289964A5019126926 @default.
• W2034289964 hasAuthorship W2034289964A5026905234 @default.
• W2034289964 hasAuthorship W2034289964A5029395182 @default.
• W2034289964 hasAuthorship W2034289964A5035120459 @default.
• W2034289964 hasAuthorship W2034289964A5038730582 @default.
• W2034289964 hasAuthorship W2034289964A5049008391 @default.
• W2034289964 hasAuthorship W2034289964A5091240925 @default.
• W2034289964 hasConcept C126322002 @default.
• W2034289964 hasConcept C143998085 @default.
• W2034289964 hasConcept C2776694085 @default.
• W2034289964 hasConcept C2778239845 @default.
• W2034289964 hasConcept C2780258809 @default.
• W2034289964 hasConcept C2781413609 @default.
• W2034289964 hasConcept C71924100 @default.
• W2034289964 hasConcept C98274493 @default.
• W2034289964 hasConceptScore W2034289964C126322002 @default.
• W2034289964 hasConceptScore W2034289964C143998085 @default.
• W2034289964 hasConceptScore W2034289964C2776694085 @default.
• W2034289964 hasConceptScore W2034289964C2778239845 @default.
• W2034289964 hasConceptScore W2034289964C2780258809 @default.
• W2034289964 hasConceptScore W2034289964C2781413609 @default.
• W2034289964 hasConceptScore W2034289964C71924100 @default.
• W2034289964 hasConceptScore W2034289964C98274493 @default.
• W2034289964 hasIssue "8" @default.
• W2034289964 hasLocation W20342899641 @default.
• W2034289964 hasLocation W20342899642 @default.
• W2034289964 hasOpenAccess W2034289964 @default.
• W2034289964 hasPrimaryLocation W20342899641 @default.
• W2034289964 hasRelatedWork W1970498696 @default.
• W2034289964 hasRelatedWork W2011851765 @default.
• W2034289964 hasRelatedWork W2072728781 @default.

• next